Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

NXGL vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NXGL
NEXGEL, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$5M
5Y Perf.-77.3%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$90.21B
5Y Perf.+196.3%

NXGL vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NXGL logoNXGL
MCK logoMCK
IndustryMedical - Instruments & SuppliesMedical - Distribution
Market Cap$5M$90.21B
Revenue (TTM)$12M$403.43B
Net Income (TTM)$-3M$4.76B
Gross Margin38.3%3.6%
Operating Margin-25.5%1.5%
Forward P/E16.7x
Total Debt$3M$8.61B
Cash & Equiv.$2M$3.98B

NXGL vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NXGL
MCK
StockDec 21May 26Return
NEXGEL, Inc. (NXGL)10022.7-77.3%
McKesson Corporation (MCK)100296.3+196.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: NXGL vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. NEXGEL, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NXGL
NEXGEL, Inc.
The Growth Play

NXGL is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 112.5%, EPS growth 10.7%, 3Y rev CAGR 77.6%
  • Lower volatility, beta 0.85, Low D/E 46.5%, current ratio 2.07x
  • Beta 0.85, current ratio 2.07x
Best for: growth exposure and sleep-well-at-night
MCK
McKesson Corporation
The Long-Run Compounder

MCK carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 339.0% 10Y total return vs NXGL's -83.1%
  • 1.2% margin vs NXGL's -24.7%
  • 0.4% yield; 18-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNXGL logoNXGL112.5% revenue growth vs MCK's 12.4%
Quality / MarginsMCK logoMCK1.2% margin vs NXGL's -24.7%
Stability / SafetyNXGL logoNXGLLower D/E ratio (46.5% vs 109.6%)
DividendsMCK logoMCK0.4% yield; 18-year raise streak; the other pay no meaningful dividend
Momentum (1Y)MCK logoMCK+7.2% vs NXGL's -77.3%
Efficiency (ROA)MCK logoMCK5.7% ROA vs NXGL's -26.9%, ROIC 74.5% vs -43.1%

NXGL vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NXGLNEXGEL, Inc.
FY 2024
Contract Manufacturing
89.1%$2M
Other Incomes
10.9%$243,000
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B

NXGL vs MCK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGNXGL

Income & Cash Flow (Last 12 Months)

MCK leads this category, winning 5 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 34584.7x NXGL's $12M. MCK is the more profitable business, keeping 1.2% of every revenue dollar as net income compared to NXGL's -24.7%. On growth, MCK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNXGL logoNXGLNEXGEL, Inc.MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$12M$403.4B
EBITDAEarnings before interest/tax-$2M$6.8B
Net IncomeAfter-tax profit-$3M$4.8B
Free Cash FlowCash after capex-$3M$6.0B
Gross MarginGross profit ÷ Revenue+38.3%+3.6%
Operating MarginEBIT ÷ Revenue-25.5%+1.5%
Net MarginNet income ÷ Revenue-24.7%+1.2%
FCF MarginFCF ÷ Revenue-21.8%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year-0.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year+27.3%+37.0%
MCK leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

NXGL leads this category, winning 2 of 3 comparable metrics.
MetricNXGL logoNXGLNEXGEL, Inc.MCK logoMCKMcKesson Corporat…
Market CapShares × price$5M$90.2B
Enterprise ValueMkt cap + debt − cash$6M$94.9B
Trailing P/EPrice ÷ TTM EPS-1.19x19.19x
Forward P/EPrice ÷ next-FY EPS est.16.66x
PEG RatioP/E ÷ EPS growth rate0.43x
EV / EBITDAEnterprise value multiple15.27x
Price / SalesMarket cap ÷ Revenue0.56x0.22x
Price / BookPrice ÷ Book value/share0.64x11.63x
Price / FCFMarket cap ÷ FCF14.66x
NXGL leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 6 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-52 for NXGL. NXGL carries lower financial leverage with a 0.46x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCK's 1.10x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs NXGL's 4/9, reflecting strong financial health.

MetricNXGL logoNXGLNEXGEL, Inc.MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity-51.7%+3.0%
ROA (TTM)Return on assets-26.9%+5.7%
ROICReturn on invested capital-43.1%+74.5%
ROCEReturn on capital employed-44.7%+43.1%
Piotroski ScoreFundamental quality 0–947
Debt / EquityFinancial leverage0.46x1.10x
Net DebtTotal debt minus cash$1M$4.6B
Cash & Equiv.Liquid assets$2M$4.0B
Total DebtShort + long-term debt$3M$8.6B
Interest CoverageEBIT ÷ Interest expense-40.04x33.79x
MCK leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $1,685 for NXGL. Over the past 12 months, MCK leads with a +7.2% total return vs NXGL's -77.3%. The 3-year compound annual growth rate (CAGR) favors MCK at 26.4% vs NXGL's -26.3% — a key indicator of consistent wealth creation.

MetricNXGL logoNXGLNEXGEL, Inc.MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-67.2%-10.5%
1-Year ReturnPast 12 months-77.3%+7.2%
3-Year ReturnCumulative with dividends-59.9%+102.1%
5-Year ReturnCumulative with dividends-83.1%+270.4%
10-Year ReturnCumulative with dividends-83.1%+339.0%
CAGR (3Y)Annualised 3-year return-26.3%+26.4%
MCK leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

MCK leads this category, winning 2 of 2 comparable metrics.

MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than NXGL's 0.85 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 73.7% from its 52-week high vs NXGL's 20.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNXGL logoNXGLNEXGEL, Inc.MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.85x-0.02x
52-Week HighHighest price in past year$2.97$999.00
52-Week LowLowest price in past year$0.56$637.00
% of 52W HighCurrent price vs 52-week peak+20.0%+73.7%
RSI (14)Momentum oscillator 0–10045.121.0
Avg Volume (50D)Average daily shares traded371K782K
MCK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

MCK is the only dividend payer here at 0.42% yield — a key consideration for income-focused portfolios.

MetricNXGL logoNXGLNEXGEL, Inc.MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$994.86
# AnalystsCovering analysts31
Dividend YieldAnnual dividend ÷ price+0.4%
Dividend StreakConsecutive years of raises18
Dividend / ShareAnnual DPS$3.07
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

MCK leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NXGL leads in 1 (Valuation Metrics).

Best OverallMcKesson Corporation (MCK)Leads 4 of 6 categories
Loading custom metrics...

NXGL vs MCK: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is NXGL or MCK a better buy right now?

For growth investors, NEXGEL, Inc.

(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus 12. 4% for McKesson Corporation (MCK). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — NXGL or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -83. 1% for NEXGEL, Inc. (NXGL). Over 10 years, the gap is even starker: MCK returned +339. 0% versus NXGL's -83. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — NXGL or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus NEXGEL, Inc. 's 0. 85β — meaning NXGL is approximately -5260% more volatile than MCK relative to the S&P 500. On balance sheet safety, NEXGEL, Inc. (NXGL) carries a lower debt/equity ratio of 46% versus 110% for McKesson Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — NXGL or MCK?

By revenue growth (latest reported year), NEXGEL, Inc.

(NXGL) is pulling ahead at 112. 5% versus 12. 4% for McKesson Corporation (MCK). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 49. 2% year-over-year, compared to 10. 7% for NEXGEL, Inc.. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — NXGL or MCK?

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -37. 8% for NEXGEL, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 5% versus -40. 9% for NXGL. At the gross margin level — before operating expenses — NXGL leads at 31. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — NXGL or MCK?

In this comparison, MCK (0.

4% yield) pays a dividend. NXGL does not pay a meaningful dividend and should not be held primarily for income.

07

Is NXGL or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). Both have compounded well over 10 years (MCK: +339. 0%, NXGL: -83. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between NXGL and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NXGL is a small-cap high-growth stock; MCK is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

NXGL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 22%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform NXGL and MCK on the metrics below

Revenue Growth>
%
(NXGL: -0.2% · MCK: 6.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.